Introduction Thienopyridines are a class of antiplatelet drugs widely used in cardiovascular disease prevention and treatment. A recent concern has come to light regarding the safety of thienopyridines because of the possible risk of malignancy. We therefore performed a systematic review and meta-analysis to evaluate the association between thienopyridine exposure and malignancy. Methods We searched the MEDLINE and EMBASE databases in March 2016 for studies that evaluated incident cancer and cancer mortality with and without exposure to thienopyridines. Relevant studies were identified, and data were extracted and analysed using random-effects metaanalysis. Results A total of nine studies (six randomised controlled trials and three cohort studies) that included 282,084 participants were included. The cancer event rate with clopidogrel and prasugrel was 3.25% and 1.58% respectively. When compared with standard aspirin or placebo, thienopyridines are not significantly associated with cancer mortality and event rate (odds ratio [OR] 1.12, 95% confidence interval [CI] 0.80-1.56, n = 3; and OR 0.92, 95% CI 0.52-1.64, n = 2, respectively. Further analyses examining clopidogrel showed no significant association with cancer event rate or malignancy-related death. When comparing prasugrel with clopidogrel, no significant association was noted for cancer event rate (OR 1.10, 95% CI 0.89-1.37, n = 2]. Subanalyses according to cancer location showed that thienopyridines are not significantly associated with malignancy mortality and/or incidence. Conclusions Our results suggest that there is currently insufficient evidence to suggest that thienopyridine exposure is associated with an increased risk of cancer event rate or mortality.
Introduction
The thienopyridines ticlodipine, clopidogrel and prasugrel are adenosine diphosphate P2Y 12 platelet receptor inhibitors that reduce platelet activation. Their widespread use in cardiovascular medicine owes much to the pivotal role that platelet activation has in the pathophysiology of many & Rafail Angelos Kotronias rafailkotronias@gmail.com cardiovascular diseases, such as myocardial infarction, stroke and peripheral vascular disease [1] . Due to their favourable profile, thienopyridines (mainly clopidogrel and, recently, prasugrel) are increasingly used in the treatment and secondary prevention of acute coronary syndrome [2] [3] [4] [5] , cerebrovascular accidents [6] [7] [8] and other peripheral vascular disease [9, 10] . Despite their efficacy in reducing major adverse cardiovascular events, secondary analyses of two randomised controlled trials (RCTs) raised concerns of a potential interplay between the increased incidence of cancer and cancer-related death with thienopyridines [11, 12] . The dual antiplatelet therapy (DAPT) study of 11,648 patients comparing the effects of continued thienopyridines versus placebo beyond 12 months in patients who underwent percutaneous coronary intervention (PCI) [12] reported that at 33 months follow-up the cancer incidence event rate was higher in the continued thienopyridine group (2.0 vs. 1.6%, p = 0.12), while cancer-related mortality was significantly higher in the continued thienopyridine group (0.6 vs. 0.3%, p = 0.02); however, the latter was not significant once cancer prior to enrolment was excluded from the analysis. Conversely, after adjusting for relevant confounders, the CHARISMA randomised controlled trial in 15,603 patients [13] showed a reduced, although not statistically significant, reduction in cancer-related mortality with aspirin and clopidogrel (adjusted hazard ratio [aHR] 0.854, 95% confidence interval [CI] 0.588-1.240) at 30 months. Similarly, a retrospective observational cohort study of clopidogrel exposure in a cohort of 41,403 newly diagnosed patients with colorectal, breast and prostate cancer reported (after adjusting for relevant confounders) no significant differences in cancer-related mortality for colorectal cancer (aHR 0.98, 95% CI 0.77-1.24), breast cancer (aHR 1.22, 95% CI 0.90-1.65) or prostate cancer (aHR 1.03, 95% CI 0.82-1.28) [14] .
A systematic review by Serebruany et al. studying the incidence of solid cancers with antiplatelet therapy reported an association between long exposure to antiplatelet therapy and increased risk of new solid cancers and cancer-related mortality, although the evidence was not sufficient to alter current practice [15] ; however, the systematic review examined a broad topic, including a limited number of heterogeneous studies without a statistical meta-analysis. Moreover, since the original review, newer studies have been published, increasing the evidence base available for analysis. The aim of this report was to perform a systematic review and metaanalysis of more contemporary studies and trials to assess whether thienopyridines increase the risk of cancer events and malignancy-related deaths.
Methods

Search Strategy
We searched the MEDLINE and EMBASE databases in February 2016 using the broad search terms (Thienopyridine OR prasugrel OR ticlopidine OR clopidogrel OR ticagrelor) AND (Cancer OR carcinoma OR malignancy OR malignant OR neoplasm OR tumour OR tumor). The coverage dates for MEDLINE were from 1946 to February 2016, and from 1974 to 29 February 2016 for EMBASE. No language restrictions were applied, and translations were not required.
Study Selection
The abstract and titles yielded by the search were screened by two independent investigators (RAK, CWW) against the inclusion criteria. Additional studies were retrieved by checking the bibliography of included studies and relevant reviews. The full text of the studies that appeared to have met the inclusion criteria were independently screened by RAK and CWW at least once to confirm eligibility for inclusion. The results were combined and subsequently reviewed by an experienced reviewer (CSK). Disagreements were resolved by consensus after consultation with MAM. A flow diagram ( Fig. 1) is provided following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) [16] .
Eligibility Criteria
We included primary studies that reported on the malignancy event rate or malignancy-related mortality after thienopyridine administration. The risk of publication bias was minimized by the inclusion of conference abstracts or presentations that met the inclusion criteria. We excluded studies that evaluated malignancy rates of ticlodipine and ticagrelor because the former is no longer clinically used and the latter is not strictly a thienopyridine. Additionally, comments, reviews and case reports were excluded from the final analysis. When duplicate reports of the same study were identified, only the report with the most complete dataset and detailed methodology description was included.
Data Collection
Data were extracted independently by two investigators (RAK, CWW) from each study into preformatted tables generated in Microsoft Word (Microsoft Corporation, Redmond, WA, USA). Data abstracted included information pertaining to the year, country, number of participants, participant inclusion criteria, evaluated antiplatelets, cancer outcomes and follow-up. To assess the quality of the included studies, we used the Cochrane Collaboration Tool for assessing the risk of bias in RCTs [17] and the Newcastle-Ottawa scale to assess the quality of non-randomised studies [18] . For studies where outcome data were not available in the primary publication, the appendices, other peer-reviewed systematic reviews and FDA reports were searched for available data. No study investigators were contacted for additional information as data were available for all included studies. Disagreements were resolved by consensus after consultation with MAM.
Data Analysis
On the basis of the availability of data, we synthesized the results using meta-analysis with quantitative pooling, graphically, or by narrative synthesis. Random and fixedeffects meta-analyses were performed by the MantelHaenszel method for dichotomous data using RevMan 5.3 (Nordic Cochrane Centre, København, Denmark) in order to estimate pooled risk ratios. Statistical heterogeneity was assessed using the I 2 statistic. The method of pooling has been previously described [19] . We performed analyses examining cancer event rate and malignancy-related mortality and, additionally, we performed sensitivity analysis to detect cancer event rates or cancer-related mortality with clopidogrel only and comparing clopidogrel with prasugrel.
Results
A total of nine studies met the inclusion criteria-six RCTS [12, 13, [20] [21] [22] [23] and three retrospective cohort studies [14, 24, 25] . The total number of participants reached 282,084, varying from 3479 [24] to 155,360 [25] . The process of study selection is presented in Fig. 1 . Data on the study design, participant number, inclusion criteria, antiplatelet drugs, cancer-specific follow-up and outcome evaluated are presented in Table 1 . Table 2 presents a descriptive quality assessment of the included studies, and Table 3 presents the reported cancer outcomes per study.
While all studies reported on clopidogrel, only two specifically reported on prasugrel [11, 21, 22] , with a wide variety in outcomes reported by each study, i.e. any cancer event rate, specific cancer event rate, or even cancer-related mortality. Cancer-specific follow-up in RCTs ranged from a minimum of 6 months to a maximum of 33 months. Mean weighted follow-up for all studies that reported on follow-up was 9.65 years [12, 14, 22, 23, 25] ; however, on exclusion of the cohort studies [14, 25] , the mean weighted follow-up was 1.83 years. By contrast, cohort studies had a mean weighted follow-up of 11.24 years.
Cancer Event Rate
The results and quality assessment of studies are presented in Tables 2 and 3 . The cancer event rate was 3.25% (1632/ 50,255) with clopidogrel [11, 13, [20] [21] [22] [23] 25 ] and 1.58% (178/11,295) with prasugrel [11, 21, 22] . Thienopyridine exposure did not associate with increased odds of cancer events (odds ratio [OR] 0.92, 95% CI 0.52-1.64, n = 2) (Fig. 2) , an observation that was retained in a sensitivity analysis with clopidogrel only (OR 0.70, 95% CI 0.66-0.75, n = 1) (Fig. 3) . A further analysis comparing prasugrel with clopidogrel showed no significant difference in cancer event rate (OR 1.10, 95% CI 0.89-1.37, n = 2) (Fig. 4 ). All the above relationships were maintained in fixed-effects analysis.
Thienopyridines and Cancer Mortality
Analysis of studies reporting on cancer mortality indicate that thienopyridine treatment versus control or aspirin was not associated with an increased odds of mortality (OR 1.12, 95% CI 0.80-1.56, n = 3) (Fig. 5) , a relationship maintained in clopidogrel-only sensitivity analysis (OR 0.85, 95% CI 0.59-1.24, n = 1) (Fig. 3 ). An analysis comparing prasugrel and aspirin with clopidogrel and aspirin suggested no significant differences in the odds of cancer mortality (OR 1.57, 95% CI 0.91-2.71, n = 1) (Fig. 4) . When compared with a random-effects model, fixed-effects meta-analysis highlighted no significant differences in the odds of cancer mortality with thienopyridines in RCTs (OR 1.09, 95% CI 0.79-1.49, n = 2), despite a numerically different result.
Thienopyridine Relation to Cancer Event Rate, by Location
Data for all thienopyridines were available for lung, colorectal, breast, prostate and hepatocellular cancer. In the case of clopidogrel, data were also available for pancreatic and haematological cancers. After pooling all studies per cancer site, thienopyridines and clopidogrel alone were associated with no significant differences in cancer event rate (Figs. 6, 7) ; however, in the hepatocellular carcinoma subgroup, clopidogrel showed a significant decrease in the risk of cancer (OR 0.27, 95% CI 0.09-0.77, n = 1). The comparison of clopidogrel with prasugrel showed no significant differences in the odds of site-specific cancer event rates (Fig. 8) , while fixed-effects meta-analysis did not reveal any differences to the random-effects meta-analysis.
Discussion
Our analysis suggests there is no evidence of a thienopyridine class effect in increasing cancer event rate or malignancy-related mortality when compared with standard aspirin or no drug. Subanalyses of cancer mortality and cancer event rates also analysed by type of medication showed no cancer signal. Indeed, our results support that the increased cancer mortality with thienopyridines is a chance finding, a hypothesis proposed by the DAPT and TRITON-TIMI 38 study investigators [12, 21] . Furthermore, our study explores contemporary evidence to examine the thienopyridine cancer hypothesis that has been put forward to explain the findings. Our results are based on both RCTs and cohort studies. Our primary analyses are largely influenced by two large, well-designed retrospective cohort studies with a long-term follow-up of 5 and 12 years, respectively. Hicks et al. [14] reported a statistically significant reduction in cancer mortality with thienopyridines (adjusted odds ratio [aOR] 0.63, 95% CI 0.55-0.73), while Leader et al. [25] reported a significant reduction in cancer event rate (aOR 0.46, 95% CI 0.44-0.49). Despite the use of multivariate analysis to adjust for potential confounders, including, but not limited to, age, sex, smoking status and duration of treatment, results from retrospective cohort studies can be influenced by unmeasured confounders, limiting subsequent inferences. Our findings are in contrast to the DAPT trial findings, which showed a statistically significant late increase in cancer mortality with prolonged dual antiplatelet therapy of aspirin and thienopyridines (0.3 vs. 0.6%, p = 0.02) [12] . However, it must be noted that in this study there was an imbalance of patients with preexisting, occasionally metastatic cancer between the two Newcastle-Ottawa scale [18] arms of the trial after randomisation [12] . Additionally, a sub-analysis excluding cancers diagnosed prior to enrolment exonerated the increased risk of cancer mortality. One possible mechanistic explanation for the previous excess of cancer is that dual antiplatelet drug regimens increase bleeding risk from pre-existing tumours, which in turn may lead to earlier tumour detection on the DAPT group, an observation that has been previously reported for anticoagulants and antiplatelets [26, 27] . Moreover, in support of this argument is that patients receiving antiplatelets have a lower rate of advanced stage (IV) colorectal carcinoma compared with the control arm, possibly due to detection of existing tumours at an earlier stage [28] . aHR adjusted hazard ratio, HR hazard ratio, OD once daily, RR risk ratio From a pathophysiological point of view, Serebruany et al. [15] hypothesized that antiplatelet medication could be responsible for the increase in cancer incidence owing to carcinogenicity of the drug and/or its components; however, this hypothesis is not supported by in vivo animal studies which showed that prasugrel and clopidogrel were not carcinogenic [11] . Regarding the mechanisms underlying cancer mortality, Serebruany et al. also suggested that disruption of the platelet-tumour niche and the subsequent enhancement of metastatic dissemination might occur. However, laboratory evidence suggests that platelets have a prometastatic function by promoting epithelial to [29] . Therefore, administration of thienopyridines should, in theory, reduce the risk of metastasis. In favour of this argument, a mouse model of lung metastasis showed that P2Y 12 -deficient mice had less tumour burden [30] . Therefore, evidence to date does not support a pathophysiological link between increased cancer mortality and thienopyridine treatment.
On an individual study level, only the DAPT and TRILOGY studies included a specialist oncology adjudication committee to minimise ascertainment bias. The potential effect of ascertainment bias on cancer mortality and event rate, given the small event rate, is important and is highlighted by a recent FDA consensus analysis [11] . Moreover, sampling bias is an inherent methodological shortfall of the two cohort studies when compared with randomised trials. Indeed, the aforementioned weaknesses in individual study design could account for the statistical heterogeneity of our results and the residual confounding of their individual results. However, subgroup analyses including only RCTs for cancer event rate and cancer mortality with thienopyridines (Figs. 2, 5) showed that cohort studies did not alter the results significantly. Therefore, our results also benefit from the extended follow-up of the included cohort studies. Our study is the first meta-analysis to address this contemporary and controversial topic using both prospective and retrospective studies. In an era of intense pharmacovigilance, our study seeks to clarify concerns raised by DAPT, especially when considering that cancer has overtaken cardiac events as the primary mortality cause after PCI [31, 32] . Additionally, the use of a random-effects model in our statistical analysis permits inferences of the results to the wider population.
Indeed, as with every meta-analysis, our work is inherently limited by the quality of the included studies. First, the studies enrolled heterogeneous populations, had different study protocols and cancer-event adjudication, and compared different durations and combinations of antiplatelet therapies. However, the heterogeneity enables examination of different populations, which would provide more in the way of identifying a phenomenon that affects a particular subpopulation. Indeed, our fixed-effects model analysis did not identify a specific at-risk subpopulation. Second, the safety (cancer event) endpoint analyses in trials are observational in nature, and conducted without a prespecified hypothesis and the necessary power calculations, predisposing individual studies to type I error. To minimise these errors, study authors grouped various cancers together to increase the event rate and simplify the analysis construct, unavoidably limiting the pathophysiological rationale. However, our sensitivity analysis by cancer location yields similar results to the pooled analysis.
Interestingly, follow-up varied greatly from study to study, with trials having shorter follow-up at risk of missing late cancers, a high possibility given the late cancer signal shown by the DAPT trial [12] . However, the study by Hicks et al. with a median follow-up of 12.9 years, showed an association of reduced cancer mortality with clopidogrel use [14] . Although the included studies mainly examined clopidogrel, DAPT examined clopidogrel and prasugrel but has not published the dichotomised data to date. The use of aspirin in the comparison group in early trials could affect the results for clopidogrel, but the direction of this effect would likely lead to an overshooting of the odds ratio as several studies suggest that aspirin reduces the cancer event rate and mortality [33] [34] [35] . Indeed, later trials (CHARISMA, DAPT, TRILOGY) have included aspirin in both groups, but the influence of this addition on cancer event rate or mortality is unexplored [12, 13, 22] .
Conclusions
To our knowledge, this is the first systematic review and meta-analysis to date examining whether thienopyridine antiplatelets increase cancer mortality and cancer events. We found the cancer event rate was 1.58% and 3.25% for prasugrel-and clopidogrel-exposed patients respectively. Our study does not support concerns for a class effect of thienopyridines in increasing the cancer event rate and/or mortality when compared with standard aspirin or no drug.
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